Charles Bennett to Drug Labeling
This is a "connection" page, showing publications Charles Bennett has written about Drug Labeling.
Connection Strength
1.188
-
Effects of the US Food and Drug Administration Boxed Warning of Erythropoietin-Stimulating Agents on Utilization and Adverse Outcome. J Clin Oncol. 2017 Jun 10; 35(17):1945-1951.
Score: 0.548
-
End of an era of administering erythropoiesis stimulating agents among Veterans Administration cancer patients with chemotherapy-induced anemia. PLoS One. 2020; 15(6):e0234541.
Score: 0.171
-
Reply to A.M. Zeidan et al. J Clin Oncol. 2017 10 01; 35(28):3265.
Score: 0.140
-
A tale of two citizens: a State Attorney General and a hematologist facilitate translation of research into US Food and Drug Administration actions--a SONAR report. J Oncol Pract. 2012 Nov; 8(6):e158-67.
Score: 0.099
-
Description of anaphylactic reactions to paclitaxel and docetaxel reported to the FDA, with a focus on the role of premedication. Expert Opin Drug Saf. 2011 Jul; 10(4):521-8.
Score: 0.091
-
Epoetin-associated pure red cell aplasia: past, present, and future considerations. Transfusion. 2008 Aug; 48(8):1754-62.
Score: 0.074
-
Low literacy impairs comprehension of prescription drug warning labels. J Gen Intern Med. 2006 Aug; 21(8):847-51.
Score: 0.065